全文获取类型
收费全文 | 5723篇 |
免费 | 410篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 171篇 |
妇产科学 | 136篇 |
基础医学 | 1055篇 |
口腔科学 | 164篇 |
临床医学 | 533篇 |
内科学 | 1066篇 |
皮肤病学 | 194篇 |
神经病学 | 751篇 |
特种医学 | 225篇 |
外科学 | 562篇 |
综合类 | 31篇 |
一般理论 | 2篇 |
预防医学 | 347篇 |
眼科学 | 84篇 |
药学 | 394篇 |
中国医学 | 8篇 |
肿瘤学 | 398篇 |
出版年
2023年 | 48篇 |
2022年 | 58篇 |
2021年 | 120篇 |
2020年 | 107篇 |
2019年 | 134篇 |
2018年 | 130篇 |
2017年 | 96篇 |
2016年 | 144篇 |
2015年 | 164篇 |
2014年 | 204篇 |
2013年 | 229篇 |
2012年 | 374篇 |
2011年 | 391篇 |
2010年 | 229篇 |
2009年 | 242篇 |
2008年 | 362篇 |
2007年 | 345篇 |
2006年 | 331篇 |
2005年 | 307篇 |
2004年 | 323篇 |
2003年 | 293篇 |
2002年 | 267篇 |
2001年 | 92篇 |
2000年 | 86篇 |
1999年 | 105篇 |
1998年 | 73篇 |
1997年 | 57篇 |
1996年 | 45篇 |
1995年 | 37篇 |
1994年 | 41篇 |
1993年 | 37篇 |
1992年 | 49篇 |
1991年 | 60篇 |
1990年 | 47篇 |
1989年 | 41篇 |
1988年 | 41篇 |
1987年 | 26篇 |
1986年 | 50篇 |
1985年 | 28篇 |
1984年 | 24篇 |
1983年 | 17篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 15篇 |
1979年 | 18篇 |
1978年 | 22篇 |
1977年 | 24篇 |
1974年 | 20篇 |
1970年 | 19篇 |
1969年 | 16篇 |
排序方式: 共有6153条查询结果,搜索用时 15 毫秒
1.
2.
We have shown previously that the plant cannabinoid cannabidiol (CBD) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. Here, we investigated whether the main psychotropic constituent of cannabis, Δ9-tetrahydrocannabinol (THC) alone or in combination with other cannabis constituents can cause similar responses, and whether THC affects the responses induced by CBD. Our experiments were performed with 1 μM pure THC (pTHC), with 1 μM pure CBD (pCBD), with a high-THC, low CBD cannabis extract (eTHC), with a high-CBD, low THC cannabis extract (eCBD), with a mixture of eTHC and eCBD (THC:CBD = 1:1) or with corresponding ‘mock extracts’ that contained only pTHC and pCBD mixed in the same proportion as in eTHC, eCBD or the 1:1 mixture of eTHC and eCBD. 相似文献
3.
Prof. Dr. Alexander Kapp Prof. Dr. Bettina Wedi 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(10):854-854
Ohne Zusammenfassung 相似文献
4.
5.
Loa Clausen Kristian Rokkedal Jan H. Rosenvinge 《European eating disorders review》2009,17(6):462-467
The Eating Disorder Inventory, Version 2 (EDI‐2) is a questionnaire used clinically and in research all over the world. EDI‐2 is cross‐culturally valid, yet normative values may depend on culture. Norms and reliability of the Danish version have to date been lacking, and will be presented in this article, comparing patients (N = 575) and controls (N = 881). Also, internal reliability of scales is tested for both groups. Differences between norms of the Danish and the North American version of EDI were small but significant for all scales except asceticism (eating disorder patients) and ineffectiveness, interpersonal distrust and maturity fears (normal controls). For both groups the internal consistency was >0.70 for all subscales except asceticism. Although differences across the eating disorder diagnostic groups were dubious, the EDI‐2 is useful to screen for eating problems in the general population as well as to rate progress and outcome among eating disorder patients. Copyright © 2009 John Wiley & Sons, Ltd and Eating Disorders Association. 相似文献
6.
Human exposure to 3-carene by inhalation: toxicokinetics, effects on pulmonary function and occurrence of irritative and CNS symptoms 总被引:5,自引:0,他引:5
Terpenes, especially 3-carene, may irritate the skin and mucous membranes and prolonged exposure may result in allergic contact dermatitis or chronic lung function impairment. The toxicokinetics of 3-carene were studied in human volunteers exposed by inhalation (2 hr 50 W) in an exposure chamber on three occasions. The exposure concentrations were approximately 10, 225, and 450 mg/m3 3-carene. The relative pulmonary uptake was high, approximately 70% for the higher exposure levels. Total uptake increased linearly with increasing exposure. The blood clearance of 3-carene observed in this study, 0.9 liter.kg-1.hr-1, indicates that 3-carene is fairly readily metabolized. About 3% of the total uptake was eliminated unchanged via the lungs while less than 0.001% was eliminated in the urine after the end of exposure. A long half time in blood was observed in the terminal phase which indicates a high affinity to adipose tissues. A statistically significant divergence between ratings of irritation during the high exposure level and during the medium and control levels was observed. The difference in airway resistance after exposure to a high concentration of 3-carene compared to control level was not significant (P = 0.02). 相似文献
7.
J. T. Andersen J. Gammelgaard L. M. Nielsen E. Clausen 《International urology and nephrology》1986,18(3):327-332
The technique and use of a percutaneous subclavian vein catheter for haemodialysis in 20 patients are reported. The catheterization procedure carried a very low morbidity, and blood flow rates of 200–250ml/min were achieved through the catheters. Use of this angioaccess saves future possible sites for permanent vascular access. Infectious complications were not encountered. Subclavian vein catheterization is a favourable alternative to external Silastic Teflon shunt. 相似文献
8.
9.
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy) 下载免费PDF全文
Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change −42.5% vs +1.4% with placebo) and total seizures (−32.1% vs −11.7% with placebo), accompanied by significantly higher responder rates. These results are comparable with findings reported for other AEDs in randomized, controlled clinical trials in patients with LGS. Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability. The most frequently reported adverse events from a pooled safety database evaluating short- and long-term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue (13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile and is a promising candidate for the adjunctive therapy of LGS. 相似文献
10.